造血细胞移植后肺炎球菌疫苗:四剂肺炎球菌结合疫苗方案的快速综述
该快速综述基于31项研究,评估造血细胞移植受者接种四剂肺炎球菌结合疫苗(PCV)方案的免疫原性和安全性。四剂PCV13方案较三剂PCV13后接PPSV23产生更高IgG和调理吞噬活性反应,第四剂后抗体反应稳健且安全性可接受。尚无研究评估PCV20或PCV21,为重要证据缺口。
要点
- 四剂PCV13方案免疫原性优于三剂PCV13后接PPSV23方案
- 移植后≥6个月启动疫苗接种常与更强更持久免疫反应相关
- 尚无研究评估PCV20或PCV21在造血细胞移植受者中的效果
核心结论
- 现有证据支持移植后3-6个月启动四剂PCV方案的免疫原性和安全性,但高价PCV等关键研究缺口仍存。
主要发现
- 4项研究直接评估异基因造血细胞移植受者的四剂PCV13或PCV15方案,仅1项提供直接随机比较。
- 在允许比较的研究中,四剂PCV13方案产生的总体和血清型特异性IgG及调理吞噬活性反应一致高于三剂PCV13后接PPSV23。
- 在末剂PCV13后1-2个月内给予PPSV23仅提供有限额外获益。
- 随机和非随机研究均显示第四剂PCV后抗体反应稳健,安全性可接受;第四剂后不良事件更频繁,但严重疫苗相关事件罕见且难以归因于基础合并症。
- 27项支持性研究显示较晚启动(移植后≥6个月)常与更强更持久免疫反应相关,但免疫力衰减仍常见;PCV方案免疫原性一致优于仅用PPSV23方案。
临床怎么用
- 对于造血细胞移植受者,可考虑在移植后3-6个月启动四剂PCV为基础的接种方案。
- 四剂PCV13方案在免疫原性上优于三剂PCV13后接PPSV23方案,PPSV23在末剂PCV13后1-2个月内追加获益有限。
局限性
- 仅4项研究直接评估四剂PCV方案,且仅1项为直接随机比较。
- 无研究评估PCV20或PCV21在造血细胞移植受者中的效果,存在重大证据缺口。
- 缺乏混合产品方案及针对移植类型或个体免疫风险定制策略的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematopoietic cell transplant (HCT) recipients are at substantially elevated risk for invasive pneumococcal disease (IPD) due to prolonged immunocompromised state, yet optimal pneumococcal vaccine product selection and scheduling, including the role of higher-valency pneumococcal conjugate vaccines (PCVs), have not undergone Advisory Committee on Immunization Practices review. We conducted a rapid review to synthesize evidence on the immunogenicity and safety of four-dose PCV schedules in HCT recipients to inform future clinical guidance. Following Cochrane rapid review methods and PRISMA guidelines, we searched Medline, Embase, and Scopus (initial: November 2024; updated: March 2025) and identified 31 eligible studies. Four studies directly evaluated four-dose PCV13 or PCV15 regimens in allogeneic HCT recipients, and only one study provided a direct randomized comparison. Among studies that allowed comparison, four-dose PCV13 schedules consistently generated higher overall and serotype-specific IgG and opsonophagocytic activity responses than three-dose PCV13 followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23), while PPSV23 provided limited additional benefit when administered within 1-2 months of the final PCV13 dose. Both randomized and nonrandomized studies demonstrated robust antibody responses following the fourth PCV dose, and safety profiles were acceptable. Although adverse events were more frequent after the fourth PCV dose, serious vaccine-related events were rare and difficult to attribute given underlying comorbidities. Findings from 27 supporting studies further contextualized optimal timing and product choice, showing that later initiation (≥6 months post-HCT) was often associated with stronger and more durable immune responses, although waning immunity remained common. PCV-based regimens were consistently more immunogenic than PPSV23-only schedules. No studies evaluated PCV20 or PCV21 in HCT recipients, representing a major evidence gap despite their expanded serotype coverage. Overall, the available evidence provides evidence of immunogenicity and safety with a four-dose PCV-based schedule initiated 3-6 months post-HCT, while critical research gaps remain regarding higher-valency PCVs, mixed-product schedules, and strategies tailored to transplant type or individual immunologic risk.
引用
- Kamitani E, Kobayashi M, Gebremichael F, et al. Pneumococcal vaccine after hematopoietic cell transplantation: a rapid review of four-dose pneumococcal conjugate vaccine schedules. Vaccine. 2026. PMID: 42966040. doi:10.1016/j.vaccine.2026.129299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。